NasdaqGS:ROIVBiotechs
Roivant Sciences Advances PHocus Trial Milestone As Shares Trade Below Targets
Pulmovant, a Roivant Sciences company, has completed patient enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease.
Enrollment finished ahead of schedule, marking a key clinical milestone for this potential first in class inhaled therapy.
For investors watching Roivant Sciences (NasdaqGS:ROIV), this clinical update adds fresh context to a stock that has seen a very large 1 year return and a 20.6% gain year to date. Shares...